Drug Database
OM

omeprazole (Omez Insta)

✓ Approved

Dr.Reddy's Laboratories Ltd. · ATP4A · Small Molecule

What is omeprazole?

omeprazole is a small molecule developed by Dr.Reddy's Laboratories Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesOmez Insta
CompanyDr.Reddy's Laboratories Ltd.
Drug ClassSmall Molecule
Molecular TargetATP4A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Dr.Reddy's Laboratories Ltd.

Mechanism of Action

Molecular Targets

omeprazole acts on 1 molecular target:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

omeprazole is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersGastritis✓ Approved

Related Research Articles

PubMedJournal of the American Veterinary Medical Association2026-07-16

Cumulative omeprazole administration is associated with increased hazard of exercise-induced pulmonary hemorrhage detection in Thoroughbred racehorses.

Jones Olivia J OJ, Ahern Benjamin J BJ, Stewart Brian D BD, Morton John M JM et al.

To evaluate associations between cumulative oral omeprazole administration and the occurrence of exercise-induced pulmonary hemorrhage (EIPH), epistaxis, atrial fibrillation, and fracture in Thoroughbred racehorses. A retrospective cohort study of 2,924 Thoroughbred racehorses in training in Hong Kong during the 2012-2013 and 2022-2023 racing seasons was performed with veterinary, training, and racing records. Time-to-event analyses were performed with Cox proportional hazards models, with cumulative omeprazole dose fitted as a time-varying covariate and adjustment for trainer, recent training intensity, racing year, and age at first trackwork. Cumulative omeprazole administration during the preceding 30 days was associated with an increased hazard of EIPH detection (hazard ratio, 1.08 for each 10-g increase; 95% CI, 1.01 to 1.15). A similar direction of association was observed for epistaxis (hazard ratio, 1.20; 95% CI, 0.99 to 1.45). Effect estimates were close to null for associations between cumulative omeprazole administration and fracture (hazard ratio, 1.02 for each 10-g increase over 60 days; 95% CI, 0.89 to 1.17) or atrial fibrillation (hazard ratio, 1.02 for each 10-g increase over 30 days; 95% CI, 0.86 to 1.20). Recent cumulative omeprazole administration was not associated with fracture or atrial fibrillation in this population of Thoroughbred racehorses. However, recent omeprazole administration was associated with an increased hazard of EIPH detection. These findings supported careful consideration of the indication and duration of omeprazole administration in racehorses, particularly when administered prophylactically.

PMID 42456746
Read full article →
PubMedInternational journal of molecular sciences2026-07-15

Evaluation of the Molecular Docking of Potential Targets and the Time-Dependent Myocardial Effects of Omeprazole in Normotensive and Spontaneously Hypertensive Rats Subjected to Cardiac Ischemia and Reperfusion.

de Aquino Filho Geraldo Teotônio GT, Felisberto Oliveira Alex Sandro AS, de Araújo Erisvaldo Amarante EA, da Silva Yamamoto Joyce Umbelino JU et al.

Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders and are generally considered safe for short-term use. However, increasing experimental and clinical evidence suggests potential cardiovascular effects associated with chronic exposure, possibly related to endothelial dysfunction and impaired nitric oxide bioavailability. Therefore, we decided to investigate whether the cardiovascular effects of omeprazole are dependent on the timing of administration in a model of cardiac ischemia-reperfusion (CIR) in normotensive Wistar rats (NWR) and spontaneously hypertensive rats (SHR). Twelve- to sixteen-week-old male NWR and SHR were allocated into four groups: (1) SHAM: NWR and SHR were submitted to surgery with no ischemia; (2) (SS + CIR): NWR and SHR were treated with a 0.9% saline solution and submitted to CIR; and (3) (OME + ISQ): NWR and SHR were treated with 10 mg/kg i.v. omeprazole (OME) before cardiac ischemia and submitted to CIR or (4) after cardiac ischemia but before cardiac reperfusion (ISQ + OME). Electrocardiograms were monitored to assess ventricular arrhythmias (VA), atrioventricular block (AVB), and lethality (LET). Serum creatine kinase-MB (CK-MB) levels were quantified, and histopathological analyses were performed to evaluate the degree of myocardial injury in the different study groups. Administration of OME prior to cardiac ischemia increased the incidence of VA, AVB, LET, and serum CK-MB levels in both NWR and SHR. In contrast, administration before cardiac reperfusion did not exacerbate cardiac injury and was associated with the attenuation of electrophysiological instability. Histopathological findings corroborated the biochemical and functional outcomes. OME, when administered prior to cardiac ischemia, worsens both cardiac arrhythmias and myocardial injury; however, administration immediately prior to cardiac reperfusion does not increase cardiac arrhythmias and decreases myocardial injury in both NWR and SHR.

PMID 42450192
Read full article →
PubMedMedComm2026-07-14

Markers Predicting Cure With Combinatorial Treatment in a Mouse Model of Latent Autoimmune Diabetes in Adults.

Sawaed Wisal W, Dallasheh Ahmad A, Eliyahu Sivan S, Aburomi Nura N et al.

Diabetes encompasses a range of diseases characterized by chronic hyperglycemia and serious health complications. However, predicting therapeutic response in latent autoimmune diabetes in adults (LADA) remains a major challenge, limiting the development of personalized treatment strategies. LADA is a relatively newly defined diabetes type that shares features of Type 1 diabetes (T1D) and Type 2 diabetes and is estimated to be more prevalent than T1D. We developed a LADA model in NOD mice and assessed combination treatment (CT) comprising GABA, sitagliptin, and omeprazole. Surprisingly, ∼30% of the CT-treated mice completely recovered, exhibiting normoglycemia and insulin independence. We identified two cell-free RNA markers, Adgrb1 and Chd5, that distinguish responders from nonresponders, indicating promising predictive ability. These discoveries offer a potential diagnostic tool for identifying LADA patients who could benefit from CT, representing an advance in personalized diabetes treatment. CT-induced β-cell neogenesis involved replication, providing valuable insights into β-cell regeneration mechanisms. Furthermore, the cured mice exhibited insulitis primarily populated by T regulatory Type 1 cells, potentially suppressing autoimmunity and facilitating β-cell survival and regeneration. This study opens new avenues for targeted LADA therapies and paves the way for precision medicine in diabetes management.

PMID 42444980
Read full article →
PubMedJournal of gastroenterology and hepatology2026-07-13

High-Dose Oral Omeprazole Versus Continuous Intravenous Pantoprazole in Patients With High-Risk Peptic Ulcer Bleeding: A Single-Blinded Multicenter RCT.

Sriyudthsak Kanteera K, Nalinthassanai Nutbordee N, Sriapiraksa Bunyos B, Rattanachaisit Pakkapon P et al.

The efficacy of high-dose oral omeprazole in peptic ulcer bleeding after successful therapeutic hemostatic endoscopy has not been well established. This study aimed to compare the efficacy of high-dose oral omeprazole versus continuous intravenous (IV) pantoprazole in rebleeding and percent time of gastric pH above 6. Eligible patients were randomized with 1:1 concealed allocation to 40-mg oral omeprazole twice daily or IV pantoprazole 8 mg/h for 72 h after index gastroscopy. Gastric pH was measured for 24 h during 48-72 h after starting the assigned medication. Rebleeding at 72 h and 30 days, as well as 24-h gastric pH, were assessed. A total of 124 patients were analyzed. Seventy-two-hour rebleeding occurred in 1.6% (1/61) of the oral omeprazole group and 4.8% (3/63) of the IV pantoprazole group requiring endoscopic hemostasis (risk difference [RD] -3.1%, 95% CI -11.6% to 4.6%). Rebleeding within 30 days also showed no difference between groups (3.3% vs. 4.8%, RD -1.5%, 95% CI -10.1% to 7.0%). Gastric pH monitoring was completed in 48% (29/61) of the oral group and 41% (26/63) of the IV group. The median percentage of gastric pH > 6 was 56.3% (IQR 28.0%-92.0%) in the oral group and 27.3% (IQR 4.4%-77.7%) in the IV group (p = 0.064). High-dose oral omeprazole may represent a feasible alternative to continuous IV pantoprazole in terms of preventing rebleeding at 72 h and 30 days and maintaining gastric pH > 6 among patients with peptic ulcer bleeding who underwent successful therapeutic hemostatic endoscopy. Registration number: NCT04394663.

PMID 42438169
Read full article →
PubMedPakistan journal of pharmaceutical sciences2026-07-12

Research on drug interactions and efficacy optimization of combined medication for elderly patients with ischemic cerebrovascular disease in Guangxi Zhuang Autonomous Region.

Chen Jiaguan J, Li Weili W, Pan Nengzhen N, Liu Zhanxi Z et al.

The incidence of ischemic cerebrovascular disease (ICVD) among the elderly in Guangxi is higher than the national average. The Zhuang ethnic group, the dominant ethnic group in the region, has unique genetic backgrounds and medication habits, often taking antiplatelet drugs and digestive system medications simultaneously, increasing the risk of drug interactions. To explore combined medication characteristics and optimize regimens for elderly ICVD patients in Guangxi, focusing on ethnic genetic differences and drug interactions. A retrospective analysis included 2135 elderly ICVD patients (873 Zhuang, 1262 Han) from 2019-2022; 807 patients received a prospective stratified regimen (2023). CYP2C19 genotypes, platelet function, and clinical outcomes were analyzed. Zhuang patients had a higher CYP2C19*3 allele frequency (28.7% vs 19.2%, P=0.004) and clopidogrel resistance rate (34.1% vs 14.7%, P<0.001). The aspirin +clopidogrel +omeprazole regimen (51.3% usage) increased stroke recurrence risk (HR=2.81). The stratified regimen boosted efficacy to 89.2%, reduced severe bleeding by 57.3%, and lowered 6-month recurrence rate from 15.7% to 8.3% (all P<0.01). Elderly Zhuang ICVD patients show distinct CYP2C19 genotypes associated with clopidogrel resistance. A genotype-liver/kidney function stratified regimen improves efficacy and safety, supporting precision medication in ethnic minority areas.

PMID 42436620
Read full article →
PubMedClinical drug investigation2026-07-10

Altered Busulphan Exposure Associated with Concomitant Omeprazole during Hematopoietic Stem Cell Transplantation Conditioning: A Two-Case Report.

El-Serafi Ibrahim I, He Rui R, Zhao Ying Y, Mattsson Jonas J et al.

Busulphan is eliminated through glutathione conjugation, forming tetrahydrothiophene, which is subsequently oxidized to tetrahydrothiophene 1-oxide and sulfolane via cytochrome (CYP)-mediated pathways, including CYP2C19 and CYP3A4. Omeprazole is a known inhibitor of CYP2C19 and may interfere with the metabolism of busulphan metabolites, thereby altering systemic busulphan exposure. Given the narrow therapeutic index of busulphan, such interactions may have clinically significant consequences. We describe two adult patients who were diagnosed with acute myeloid leukemia and received oral busulphan (twice daily [b.i.d.]) at a dose of 2 mg/kg for two consecutive days (168 mg and 150 mg, respectively) as part of fludarabine/busulphan conditioning prior to hematopoietic stem cell transplantation. Both patients received concomitant treatment with omeprazole. Unexpectedly elevated busulphan plasma area under the curve (AUC) values were observed following the initial dose despite standard dosing (14.311 and 19.378 mg·h/L, respectively). Dose reduction in one patient did not normalize systemic exposure, whereas discontinuation of omeprazole in the second patient only was followed by a marked decrease in busulphan levels. On the second day, the corresponding AUC values were 19.320 (135%) and 13.772 mg·h/L (71%), respectively. In these cases, a potential drug-drug interaction was observed between omeprazole and busulphan, possibly mediated through inhibition of CYP-dependent metabolism of busulphan metabolites. Concomitant use of omeprazole during busulphan conditioning should be avoided whenever possible. Therapeutic drug monitoring remains essential to optimize busulphan exposure and minimize the risk of treatment-related toxicity.

PMID 42430120
Read full article →

+9664 more articles available with a free account

Sign up free to view all articles →

Ask about omeprazole